All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MDS Alliance.
During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the MDS Hub spoke to Rafael Bejar, University of California San Diego, San Diego, US. We asked, Can changes in DNA methylation pattern predict the response to hypomethylating agents (HMA) in MDS.
Can changes in DNA methylation pattern predict the response to HMA in MDS?
Bejar discusses a study from ASH 2020, examining whether DNA methylation status before and during therapy could predict eventual response in patients treated with azacitidine plus the novel agent pevonedistat.
RIC allo-SCT vs HMA or best supportive care in older patients with high-risk MDS
The BMT CTN designed the phase II randomized trial 1102 (NCT02016781), to assess the benefits of reduced intensity conditioning (RIC) allo-SCT vs non-transplant...
When should we consider allo-SCT for patients with MDS?
Corey Cutler talks about the results from the Blood and Marrow Transplant Clinical Trials Network study 1102.
Subscribe to get the best content related to MDS delivered to your inbox